Focused On-demand Library for Large ribosomal subunit protein mL65

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9NP92

UPID:

RT30_HUMAN

Alternative names:

39S ribosomal protein S30, mitochondrial; Large ribosomal subunit protein mS30; Programmed cell death protein 9

Alternative UPACC:

Q9NP92; Q96I91; Q96Q19; Q9H0P8; Q9NSF9; Q9NZ76

Background:

The Large ribosomal subunit protein mL65, also known as 39S ribosomal protein S30, mitochondrial, and Programmed cell death protein 9, plays a crucial role in mitochondrial function and apoptosis. Its involvement in the mitochondrial ribosome suggests a key role in protein synthesis within mitochondria, essential for cellular energy production and regulation of cell death pathways.

Therapeutic significance:

Understanding the role of Large ribosomal subunit protein mL65 could open doors to potential therapeutic strategies. Its pivotal role in mitochondrial function and apoptosis pathways makes it a promising target for drug discovery efforts aimed at treating mitochondrial disorders and diseases characterized by dysregulated apoptosis.